DermTech Company Description
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.
The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.
It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.
In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials.
Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners.
It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 208 |
| CEO | Bret Christensen |
Contact Details
Address: 12340 El Camino Real San Diego, Delaware 92130 United States | |
| Phone | 858 450 4222 |
| Website | dermtech.com |
Stock Details
| Ticker Symbol | DMTKQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US24984K1051 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Bret Christensen | Chief Executive Officer |
| Kevin Sun | Chief Financial Officer |
| Steve Kunszabo | Head of Investor Relations |